Sign up for our daily briefing

Make your busy days simpler with the Axios AM and PM newsletters. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to the Axios Closer newsletter for insights into the day’s business news and trends and why they matter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with the Axios Sports newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with the Axios Des Moines newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with the Axios Tampa Bay newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Aïda Amer/Axios

Advocates of lowering prescription drug prices are beginning to use an expensive new Alzheimer's drug to make the case for reform, but actually addressing the therapy's price raises complicated policy challenges.

Why it matters: Democrats may be positioning themselves to push policy measures that assign value to drugs and then price them accordingly. If successful, that could be a huge blow to the pharmaceutical industry.

The big picture: Many of the policies that aim to lower drug prices are rooted in the belief that Americans shouldn't pay so much more than the rest of the world for drugs, and that old drugs shouldn't be able to become significantly more expensive over time.

  • But Biogen's Aduhelm is a brand-new drug that isn't yet approved in any other country.
  • To truly address its launch price, policymakers will have to grapple with big questions that the U.S. system currently avoids: How should we determine the value of a drug, and who gets to make that decision?
  • Right now, drug companies make pricing decisions based almost entirely on what the market will bear, and Medicare generally covers drugs that get approved by the FDA.

What they're saying: "This is the scenario where the health technology assessments done in other countries become valuable," said Walid Gellad, a medicine and health policy professor at the University of Pittsburgh.

  • "They have a country-wide mechanism in place to try and identify a fair price for the drug, based on the incremental benefit it brings. We don’t have that in the US."

Between the lines: Democrats' most prominent drug legislation is a House bill that gives Medicare the power to negotiate drug prices, and then allows private insurers access to those prices as well.

  • The bill uses prices paid by other countries — or reference pricing — to cap what the U.S. will pay for that same drug. If there isn't an international reference price, the bill allows Medicare to pay a maximum of 85% of the average manufacturer price.
  • Biogen has said Aduhelm will have a list price of $56,000, which critics say is many times its value. To these critics, a price ceiling of $47,600 may not be enough of an improvement.

What we're watching: During the campaign, President Biden proposed giving an independent review board the power to determine the Medicare rate for new drugs that don't have any competition.

  • Sen. Ron Wyden, the chairman of the Finance Committee, recently called out Aduhelm by name in a document outlining the principles that will guide the Senate's drug pricing bill, a hint that the Senate's legislation will take a different direction than the House's.
  • "Many [drugs], like the recently-approved Alzheimer’s drug Aduhelm, launch at prices far beyond any reasonable justification of the clinical value to patients, caregivers, or society. Medicare does not currently have the requisite tools to ensure a fair price for such a drug," the document states.

The bottom line: "Any kind of process for valuing new drugs like Aduhelm take you immediately into the controversial quagmire of how to quantify improvements in quality of life for people," said KFF's Larry Levitt.

  • "Aduhelm presents the added complication that it’s not even very clear yet that it will improve people’s quality of life."

Go deeper: How other countries set their drug prices

Go deeper

Kate Marino, author of Markets
Oct 5, 2021 - Economy & Business

What's behind the rising energy prices

Illustration: Sarah Grillo/Axios

Energy prices are climbing around the world amid a perfect storm of extreme weather, rising power demand, and supply constraints. It’s roiling markets overseas, with China and India facing electricity crises while a dozen power companies in the U.K. have gone belly-up.

Driving the news: Oil prices jumped again Monday after OPEC decided not to boost production beyond the modest increase that it had previously outlined.

Ben Geman, author of Generate
Oct 5, 2021 - Energy & Environment

Global energy crunch pushes prices up in U.S., Europe

Illustration: Aïda Amer/Axios

European natural gas prices soared to fresh records this morning while U.S. oil prices are at seven-year highs, the latest signs of convulsions in the global energy system that could shake climate policies.

By the numbers: Via Bloomberg, benchmark Dutch gas futures rose another 18% in trading today, with British prices seeing a similar bounce.

Mike Allen, author of AM
5 mins ago - Economy & Business

Charted: GOP surged as Biden slumped

Expand chart
Reproduced from Gallup. (Independents were asked their party leaning.) Chart: Axios Visuals

Gallup polling found a huge shift in party preference over the course of 2021, from a 9-point Democratic advantage in the first quarter to a 5-point Republican edge in the fourth quarter.

Why it matters: It's the biggest swing in one calendar year for Gallup's 30 years of tracking.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!